TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Abstract

TERC is a likely target of the 3q26 amplification, and, therefore, may be a useful biomarker for diagnosis and an attractive, novel target for molecular therapy of NSCLC.